ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time – Yahoo Finance

ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time – Yahoo Finance

GARDEN CITY, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022. A press release detailing these results will be issued prior to the call.

ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Thursday, August 11, 2022
11:00 a.m. Eastern time, 8:00 a.m. Pacific time
Participants can register for the conference call by navigating to:
Please note that registered participants will receive their dial in number upon registration. Pre-registration required fields of information include: name, phone, company, email.
Those without internet access or unable to pre-register may dial in to the conference call by calling:
Toll free dial in number:
International dial in number:
Please call the conference telephone number 5-10 minutes prior to the start time. Please ask to be joined into the ProPhase Labs, Inc. conference call. An operator will register your name, phone and organization.

The conference call will be broadcast live and available for replay at and via the investor relations section of the Company’s website at
A replay of the conference call will be available two hours from when the call ends.
Toll-free replay number:
International replay number:
Replay Access Code:
About ProPhase Labs

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a diversified diagnostics, genomics and biotech company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. The Company also continues to operate a state-of-the-art contract manufacturing subsidiary and the TK Supplements line of dietary supplements, distributed in food, drug and mass stores throughout the country.
ProPhase Diagnostics, Inc., a wholly owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing. We have announced plans for the expansion of the lab to include traditional clinical testing and genomics testing.
ProPhase Precision Medicine, Inc., a wholly owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. We are currently selling Nebula Genomics whole genome sequencing products direct-to-consumer online, with plans to sell in food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research.
ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds beginning with Equivir and Equivir G. PBIO announced a second licensing agreement for two small molecule PIM kinase inhibitors, Linebacker LB-1 and LB-2, in July 2022, with plans to pursue development and commercialization of LB-1 as a cancer co-therapy.
ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Pharmaloz contract manufacturing subsidiary.
ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.
For more information, visit
ProPhase Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
[email protected]
ProPhase Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
[email protected]

Related Quotes
Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MGIC Investment (MTG) Q2 results reflect higher premiums, partially offset by higher expenses
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd…
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Central Garden (CENT) delivered earnings and revenue surprises of 10.32% and 2.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Participants on today's call are Evan Loh, M.D., chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer. Michael Bigham, executive chairman, and I will also be available for questions.
Yahoo FInance's Allie Canal breaks down second-quarter earnings for Warner Bros. Discovery.
Look beyond the popular growth stocks. A healthy stream of income awaits.
In this article, we discuss 10 stocks that will benefit from the CHIPS Act. If you want to see more stocks in this selection, click 5 Stocks That Will Benefit from CHIPS Act. The Chips and Science Act will provide grants and subsidies worth $280 billion to the US technology and semiconductor industry. The National […]
Is the bear market over? This is the question that everyone wants to know. After a near-historic decline over the first half of the year, the stock market has been on a roll over the past month, with the S&P 500 rising nearly 9%, while the Nasdaq is up 14%. JPMorgan's chief global markets strategist Marko Kolanovic has an upbeat message for those concerned about the sustainability of the rally. “Risk markets are rallying despite some disappointing data releases, indicating bad news was already a
Tesla, Amazon, Google-parent Alphabet, GameStop and Shopify have announced or carried out stock splits in 2022. So what is a stock split and how does it affect your investment?
The indexes were quiet before the July jobs report tests the Fed's soft landing. Tesla shareholders OK'd a 3-for-1 stock split.
Twilio (TWLO) delivered earnings and revenue surprises of 45% and 2.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
These stocks might give your portfolio a boost.
The fintech co-founded by Jack Dorsey reports a second-quarter loss of $208 million, or 36 cents a share, for the three months ended June 30.
Palantir's second-quarter 2022 revenues are expected to have increased year over year.
Even AMTD Digital seems to be at a loss as to why it is now so valuable.
Star Bulk Carriers (SBLK) delivered earnings and revenue surprises of 14.29% and 10.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sometimes, what goes down must come up. After more than 5 months of losses to start the year, we’ve just had some 6 weeks of gains, featuring a 13% rebound in the S&P 500 and a 19% jump in the NASDAQ. We still don’t know if this rally will be a short-term phenomenon in a larger bear market, or if it will turn out to be a more sustained bull run – but either way, investors can turn to the data to find solid stock choices. But which data? If there’s one thing always certain in the stock market, it
In 2020, MicroStrategy stock was stagnant, and the tech company struggled to compete with software giants. On Tuesday, MicroStrategy announced Mr. Saylor would step down as CEO, a position he has held since 1989, amid mounting losses tied to bitcoin. In total, MicroStrategy raised $2.4 billion in debt and loans.


About the Author

Leave a Reply

error: Konten dilindungi !!
adana eskort - eskişehir eskort - eskort mersin